M2 Pharma - Therapy Areas - Inflammatory Disease

FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira

19 October 2021 - - The US Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases, the agency said.

Cyltezo (a...

First Patient Dosing in a Phase II Study of Tenalisib in Locally Advanced or Metastatic Breast Cancer Patients

18 October 2021 - - Switzerland-based biopharmaceutical company Rhizen Pharmaceuticals AG has commenced dosing in a phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K δ/&g...

First Patient Dosed in Phase 1 Clinical Trial Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2, in Patients with Advanced Solid Tumors

15 October 2021 - - The first patient has been dosed in US-based cancer immunotherapy company Immune-Onc Therapeutics, Inc's first-in-human clinical trial of IO-108, a novel antagonist antibody t...

Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense Tavneos, an Adjunctive Treatment for ANCA-Associated Vasculitis

15 October 2021 - - US-based Amber Specialty Pharmacy will begin dispensing Tavneos (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as an adjunctive tre...

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin's Lymphoma

15 October 2021 - - US-based Exelixis, Inc. (NASDAQ: EXEL) has exercised its exclusive option under its July 2019 agreement with Aurigene Discovery Technologies Ltd. to in-license XL114 (formerly...

Quanterix Granted Breakthrough Device Designation from US FDA for Blood-Based pTau-181 Assay for Alzheimer's Disease

12 October 2021 - - US-based digital health solutions company Quanterix Corp's (NASDAQ: QTRX) Simoa phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device designation by ...